FY2026 EPS Estimates for Atyr PHARMA Lowered by Analyst

Atyr PHARMA INC (NASDAQ:ATYR) – Analysts at HC Wainwright cut their FY2026 earnings per share estimates for Atyr PHARMA in a research note issued on Tuesday, April 29th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.66) per share for the year, down from their prior estimate of ($0.53). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Atyr PHARMA’s FY2027 earnings at $0.39 EPS and FY2028 earnings at $0.50 EPS.

Atyr PHARMA (NASDAQ:ATYR) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05.

Several other equities analysts have also commented on ATYR. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Trading Up 7.8 %

NASDAQ:ATYR opened at $3.60 on Friday. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The business’s 50-day moving average is $3.29 and its two-hundred day moving average is $3.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The firm has a market capitalization of $319.89 million, a PE ratio of -3.83 and a beta of 0.95.

Hedge Funds Weigh In On Atyr PHARMA

Several institutional investors and hedge funds have recently made changes to their positions in ATYR. Group One Trading LLC bought a new stake in shares of Atyr PHARMA in the fourth quarter worth $26,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth about $36,000. Victory Capital Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth about $37,000. Raymond James Financial Inc. acquired a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $39,000. Finally, XTX Topco Ltd acquired a new position in Atyr PHARMA in the fourth quarter worth about $40,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.